These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16283539)

  • 41. The use of the noninferiority analysis in clinical studies.
    Bermingham EC; del Castillo JR; Radecki SV
    Equine Vet J; 2014 Jul; 46(4):399-401. PubMed ID: 24909652
    [No Abstract]   [Full Text] [Related]  

  • 42. Development of new drugs in man: a review.
    Davies IB; Grind IM; Pottage A; Turner P
    J R Soc Med; 1986 Feb; 79(2):96-9. PubMed ID: 3512825
    [No Abstract]   [Full Text] [Related]  

  • 43. Limitations on the discovery and supply of medicines.
    Weatherall M
    Proc R Soc Med; 1974 Dec; 67(12 Pt 2):1287-92. PubMed ID: 4449879
    [No Abstract]   [Full Text] [Related]  

  • 44. THE IMPACT OF THE NEW FOOD AND DRUG LAWS AND REGULATIONS ON THE SPONSORS OF CLINICAL TRIALS.
    HEIN JW
    J Oral Ther Pharmacol; 1964 Jul; 1():85-92. PubMed ID: 14204420
    [No Abstract]   [Full Text] [Related]  

  • 45. Regulators and industry tackle dose-finding issues.
    Mullard A
    Nat Rev Drug Discov; 2015 Jun; 14(6):371-2. PubMed ID: 26027527
    [No Abstract]   [Full Text] [Related]  

  • 46. Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence.
    Chen ML; Blume H; Beuerle G; Mehta M; Potthast H; Brandt A; Schug BS; Ducharme M; Endrenyi L; Gallicano K; Schuirmann D; Welink J
    Eur J Pharm Sci; 2019 Jan; 127():24-28. PubMed ID: 30342171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug development, regulation, and the practice of medicine.
    Wardell WM
    JAMA; 1974 Sep; 229(11):1457-61. PubMed ID: 4408186
    [No Abstract]   [Full Text] [Related]  

  • 48. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).
    Musuamba FT; Manolis E; Holford N; Cheung S; Friberg LE; Ogungbenro K; Posch M; Yates J; Berry S; Thomas N; Corriol-Rohou S; Bornkamp B; Bretz F; Hooker AC; Van der Graaf PH; Standing JF; Hay J; Cole S; Gigante V; Karlsson K; Dumortier T; Benda N; Serone F; Das S; Brochot A; Ehmann F; Hemmings R; Rusten IS
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):418-429. PubMed ID: 28722322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laws promote pediatric drug development.
    Kuehn BM
    JAMA; 2006 Jul; 296(3):271. PubMed ID: 16849655
    [No Abstract]   [Full Text] [Related]  

  • 52. [Drugs for adults--and for the children?].
    Kalikstad B; Gramstad L
    Tidsskr Nor Laegeforen; 2005 Jun; 125(11):1470. PubMed ID: 15940308
    [No Abstract]   [Full Text] [Related]  

  • 53. [The industrialisation of therapeutic agents: a story of practices between science, technology, medicine and the law].
    Gaudillière JP
    Gesnerus; 2007; 64(1-2):93-108. PubMed ID: 17982961
    [No Abstract]   [Full Text] [Related]  

  • 54. European scheme to develop drugs for diseases with no treatment launched.
    Hawkes N
    BMJ; 2016 Mar; 352():i1385. PubMed ID: 26957004
    [No Abstract]   [Full Text] [Related]  

  • 55. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
    Stephenson T
    Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European Generic Medicines Association (EGA)--16th Annual Conference.
    Kennedy B
    IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of factors associated with dose differences between Japan and the United States.
    Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
    Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.
    Hh B; M M; G B; A D; G H; W J; A K; J L; H P; B S; A S; N T; Tsang YC; J W; J W
    Eur J Pharm Sci; 2021 Dec; 167():105987. PubMed ID: 34481066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generic Pharmaceutical Industry Association Orphan Drug Institute.
    Haddad W
    Prog Clin Biol Res; 1985; 197():41-5. PubMed ID: 4070298
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmaceutical stability testing conference.
    Shi L; Schofield T
    Expert Opin Drug Saf; 2004 Mar; 3(2):153-8. PubMed ID: 15006721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.